There were no significant differences in sex, age, HBsAg, cirrhosis, BCLC stage, Child-Pugh classification, AFP level, tumour diameter, node number, metastasis, portal vein thrombosis, TACE-RFA procedures and time interval between TACE and RFA treatment in the training and validation cohorts (Table 1). This evidence concerns the gene AFP and Cirrhosis.